Qatari German Company for Medical Devices (Q.P.S.C.) ($QGMD)

Earnings Call Transcript · April 21, 2026

DSM QA Health Care Health Care Equipment and Supplies Earnings Calls 7 min

Highlights from the call

In Q4 FY 2025, Qatari German Company for Medical Devices reported a significant net loss of QAR 68.5 million, contrasting with a profit of QAR 9.3 million in the previous year. The earnings per share (EPS) declined to QAR 0.0803 from QAR 0.5929, indicating substantial financial challenges. Management signaled that logistics costs are expected to rise by 80% in the near term, which could impact Q1 and Q2 results, but they anticipate improvements in the second half of 2026.

Main topics

  • Net Loss Reporting: The company reported a net loss of QAR 68,485,914 for FY 2025, a stark contrast to a profit of QAR 9,274,610 in FY 2024. Management acknowledged the financial challenges faced during the year, stating, 'Despite the financial challenges... a clear future plan was approved.'
  • Decline in EPS: Earnings per share fell to QAR 0.0803 from QAR 0.5929 year-over-year. This decline reflects the overall financial difficulties the company is experiencing, as noted by management during the call.
  • Logistics Cost Increase: Management indicated a projected 80% increase in logistics costs, particularly for products sourced from France, India, and China. They mentioned, 'If we get support regarding the additional amount, then we will be fine,' highlighting dependency on government support.
  • Future Operational Improvements: Management expressed optimism for future performance improvements, stating, 'We are promised by the next year that our company will show a great performance.' They are focusing on enhancing operational efficiency and negotiating with suppliers.
  • Government Support Dependency: The company’s future performance may hinge on government support for logistics costs. Management noted that without this support, the financial impact could be significant in the first half of 2026.

Key metrics mentioned

  • Net Profit: QAR -68,485,914 (vs QAR 9,274,610 profit in FY 2024)
  • Earnings Per Share (EPS): QAR 0.0803 (vs QAR 0.5929 in FY 2024)
  • Logistics Cost Increase: 80% (Projected increase affecting Q1 and Q2 2026)
  • Operational Efficiency Initiatives: Initiated (Focus on enhancing performance through negotiations)

The significant net loss and declining EPS raise concerns about QGMD's financial health and operational efficiency. Investors should monitor the company's ability to manage logistics costs and the effectiveness of its operational improvement plans, as well as the potential for government support to mitigate rising expenses.

Earnings Call Speaker Segments

Operator

Operator
#1

Hello, everyone. Thank you so much for standing by, and welcome to Qatar German Medical (sic) [ Qatari German for Medical Devices ]. Please note that this call is being recorded. [Operator Instructions] I'd like to hand the call over now to our moderator, Phibion, please go ahead.

Phibion Makuwerere

Analysts
#2

Thank you, Gail. Good afternoon to you all, and I would like welcome you all to the Qatari German for Medical Devices 4Q and FY 2025 earnings conference call. On the call today from Qatari Medical devices, we have Abdulaziz Mohamed [ sad ] Al-Tamimi, who's the Managing Director. And we also have [indiscernible], the accountant. And on the call today, they will first go over the performance of the company over the year 2025 and Q4. And then after that, we have a Q&A session. Let me turn over the call to Abdulaziz to begin the call. Please go ahead, sir.

Abdulaziz Muhammad Al-Tamimi

Executives
#3

Thank you. Greeting to our shareholders. We are pleased today to present to you the company's results for the fourth quarter of the financial year 2025, which reflects a stable improvement in overall performance other rest of the [indiscernible] and organization effort. Qatari German for Medical Devices disclosed the financial statement for 12 months period ended on 31 December 2025. The Financial Services [ a net ] profit of QAR 9,274,610. And conversion to net loss of QAR 68,485,914 for the same period of [ this ] year. The profit per share amounted to QAR 0.0803 as of December 31, 2025, [ versus ] per share, QAR 0.5929 of the same breed in 2024. Despite the financial challenges and the difficulties faced by the [ comment ] during the first half of the year. A clear future plan was approved in July [ 2025 ] of the company's position as [indiscernible] has already commenced through the internal interaction aimed to enhancing operational efficiency and elevating an institutional performance. A lot of improvement operational, the company initiated negotiation process with suppliers and partners to make sure that our operating cost would maintain the quality of products interest without any [ component ]. And [Foreign Language] we are promised by the next year that our company will show a great performance. Thank you.

Phibion Makuwerere

Analysts
#4

Gil, I think you can open the line for questions.

Operator

Operator
#5

[Operator Instructions] All right. Since I think there are no questions at this time, I would like to turn the call back over to Phibion. Thank you.

Phibion Makuwerere

Analysts
#6

I suppose before I close, let me just ask a very high-level question. Given the environment that we are in, do you have any guidance for the next quarter or for the rest of the year? And if you're experiencing any challenges around logistics supply chain?

Abdulaziz Muhammad Al-Tamimi

Executives
#7

Okay. Regarding logistics, our country [Foreign Language] to support the local company that manufactures as well. So we already will pace an increase in around 80% on the logistic. Especially, we have products from France, India and China. So it costs as high, but we will try to manage [Foreign Language]. And for quarter, maybe 1 and 2, we will face an increasing on the logistic cost, but that will depend as well with the government support. If we get support regarding the additional amount, then we will be fine that there will be no [ back ] maybe up to 20% to 30%. But if there is no support receiving in the first 2 quarters, it will show in our financial year for the first quarter of 2026. How far? It might be improving by the second half of the year.

Phibion Makuwerere

Analysts
#8

All right. Thank you. That sort of helps to paint the picture of what we might expect. If there are no further questions on the line, I can close off the call. Can you just check for me one more time, Gail, if there are any more questions before I close?

Operator

Operator
#9

Yes. So upon checking in the queue there are no questions at this time. So I think we can go ahead to conclude this call for today. Thank you.

Phibion Makuwerere

Analysts
#10

All right. Thank you for joining us, and please do join us for Q1 earnings call, and have a good day, and thanks to the management team.

Abdulaziz Muhammad Al-Tamimi

Executives
#11

Thank you.

Operator

Operator
#12

Thank you, everyone. And that concludes our call for today. Thank you. You may now disconnect. Have a nice day ahead.

For developers and AI pipelines

Programmatic access to Qatari German Company for Medical Devices (Q.P.S.C.) earnings transcripts and 32,000+ others is available through the EarningsCalls.dev REST API. Plans from $24.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.